No Evidence of Sex-Based Differences in Midazolam Administration Frequency
The available evidence does not support that women are given midazolam (Versed) more frequently than men before procedures or surgery. Current guidelines and drug labeling do not recommend sex-based differences in the decision to administer midazolam for procedural sedation, and there is no clinical evidence demonstrating differential prescribing patterns based on sex alone.
What the Evidence Shows
Guideline Recommendations Are Sex-Neutral
The major procedural sedation guidelines make no distinction between male and female patients regarding when to administer midazolam 1, 2, 3. The 2018 ASA Practice Guidelines for Moderate Procedural Sedation explicitly state that benzodiazepines like midazolam can be used for procedural sedation without any sex-specific recommendations 3. Similarly, the AGA Institute reviews and multisociety sedation curricula for gastrointestinal endoscopy describe midazolam dosing and administration protocols that apply equally to both sexes 1, 2, 1, 2.
Dosing Adjustments Are Based on Age and Comorbidities, Not Sex
The FDA-approved labeling for Versed (midazolam) provides detailed dosing guidance based on:
- Age (patients over 60 require 20-50% dose reduction)
- ASA physical status (higher risk patients need lower doses)
- Concomitant medications (30% reduction with opioids)
- Organ dysfunction (hepatic or renal impairment requires adjustment)
Notably absent from this list is any recommendation to adjust dosing or frequency based on patient sex 4.
Pharmacokinetic Differences Don't Translate to Clinical Practice Changes
While one recent study found that women may metabolize remimazolam (a related benzodiazepine) more rapidly than men, this did not result in clinically significant differences in emergence times 5. The study authors concluded that despite pharmacokinetic differences, these did not affect clinical outcomes under combined anesthesia. This suggests that even when sex-based metabolic differences exist, they may not warrant different prescribing practices.
The Real Issue: Underrepresentation in Research
The more significant problem is that women are systematically underrepresented in clinical trials. A review of cardiovascular trials found only 30.6% women enrolled, with only one-third reporting sex-specific results 6. For heart failure drug trials specifically, only 48% reported sex-specific efficacy data and just 9% presented sex-specific adverse drug reaction information. This means we lack adequate evidence to determine whether sex-based differences in midazolam administration should exist, not that they currently do.
Clinical Algorithm for Midazolam Administration
The decision to administer midazolam should follow this hierarchy:
- Indication assessment: Is procedural sedation/anxiolysis needed? 4
- Risk stratification:
- Age ≥60 years → reduce initial dose by 20-50%
- ASA class III or higher → reduce dose
- COPD or respiratory disease → use caution
- Concurrent opioids/CNS depressants → reduce dose by 30%
- Dosing: Start with 1-2 mg IV over 2 minutes for adults <60 years; 1 mg for elderly 4
- Titration: Wait 2+ minutes between doses to assess effect
- Monitoring: Continuous respiratory and cardiac monitoring required 3
Sex is not a factor in this decision tree.
Important Caveats
- Elderly women may require lower doses, but this is due to age-related pharmacokinetic changes, not sex per se 1
- The American Geriatrics Society Beers Criteria recommend avoiding benzodiazepines in all patients ≥65 years (both sexes) due to delirium and fall risk 7, 8
- Pregnancy status (relevant only to women) would be a contraindication, but this is a physiologic state, not a sex-based difference in standard practice
The question of whether prescribing should differ by sex cannot be answered with current evidence due to inadequate representation of women in clinical trials and lack of sex-stratified outcome reporting.